Sugi Predict

Sugi Predict / Compounds / SCHEMBL813709

SCHEMBL813709

SCHEMBL813709

Cc1ccc(NC(=O)NC2CCCCC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EPHX1 P07099 13/20 1.00
▸ RAB9A P51151 11/20 1.00
▸ NPC1 O15118 9/20 1.00
▸ SMN1; SMN2 Q16637 4/20 0.74
▸ POLB P06746 1/20 0.74
▸ MAPT P10636 1/20 0.74
▸ EPHX2 P34913 5/20 0.71
▸ ALDH1A1 P00352 1/20 0.71
▸ CYP2C9 P11712 1/20 0.71
▸ CYP2C19 P33261 1/20 0.71
▸ MEN1 O00255 1/20 0.71
▸ KMT2A Q03164 1/20 0.71
▸ GAA P10253 1/20 0.71
▸ TP53 P04637 1/20 0.70
▸ NFKB1 P19838 1/20 0.70
▸ NFKB2 Q00653 1/20 0.70
▸ RELA Q04206 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2750450 0.98 EPHX1 (0.97) EPHX1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL12407164 0.95 EPHX1 (0.90) EPHX1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL12407204 0.91 EPHX1 (0.84) EPHX1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL17854894 0.91 EPHX1 (0.83) EPHX1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL13756244 0.91 EPHX1 (0.86) EPHX1RAB9ANPC1SMN1; SMN2EPHX2
SCHEMBL17189476 0.90 EPHX1 (0.81) EPHX1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL13756248 0.89 EPHX1 (0.83) EPHX1RAB9ANPC1SMN1; SMN2EPHX2
SCHEMBL23573481 0.87 EPHX1 (0.77) EPHX1RAB9ANPC1SMN1; SMN2POLB
SCHEMBL8391687 0.85 EPHX1 (1.00) EPHX1RAB9ANPC1SMN1; SMN2EPHX2
SCHEMBL12196184 0.85 EPHX1 (1.00) EPHX1RAB9ANPC1SMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6630512-B2 Antiinflammatory agents; autoimmune disease BIOGEN, INC. 2003-10-07 — — US claimed
US-6624152-B2 Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases BIOGEN, INC. 2003-09-23 — — US claimed
US-20030083267-A1 Cell adhesion inhibitors BIOGEN, INC., A MASSACHUSETTS CORPORATION 2003-05-01 — — US claimed
US-20030018016-A1 Cell adhesion inhibitors BIOGEN IDEC MA, INC. 2003-01-23 — — US claimed
EP-0805796-B1 CELL ADHESION INHIBITORS BIOGEN INC (US) 2002-12-11 — — EP claimed
US-6376538-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES BIOGEN, INC. 2002-04-23 — — US claimed
US-6306840-B1 ANTISTICKING AGENTS OF OLIGOPEPTIDES BIOGEN, INC. 2001-10-23 — — US claimed
WO-2024017518-A1 LUBRICATING GREASE COMPOSITION CONTAINING AN IONIC FLUID KLUEBER LUBRICATION MUENCHEN SE & CO. KG (DE) 2024-01-25 — — WO disclosed
EP-4310163-A1 GREASE COMPOSITION COMPRISING AN IONIC LIQUID Klüber Lubrication München SE & Co. KG (DE) 2024-01-24 — — EP disclosed
EP-4239039-A1 LUBRICATING COMPOSITION COMPRISING AN IONIC LIQUID Klüber Lubrication München SE & Co. KG (DE) 2023-09-06 — — EP disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 — — US disclosed
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 — — US disclosed
EP-2933321-B1 GREASE COMPOSITION AMELIORATING LOW-TEMPERATURE FRETTING KYODO YUSHI (JP) 2019-02-13 — — EP disclosed
US-20030018016-A1 Cell adhesion inhibitors BIOGEN IDEC MA, INC. 2003-01-23 — — US disclosed
EP-0805796-B1 CELL ADHESION INHIBITORS BIOGEN INC (US) 2002-12-11 — — EP disclosed
US-6376538-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES BIOGEN, INC. 2002-04-23 — — US disclosed
US-6306840-B1 ANTISTICKING AGENTS OF OLIGOPEPTIDES BIOGEN, INC. 2001-10-23 — — US disclosed
EP-1142867-A2 Cell adhesion inhibitors BIOGEN, INC. (US) 2001-10-10 — — EP disclosed
EP-0805796-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1997-11-12 — — EP disclosed
WO-1996022966-A1 CELL ADHESION INHIBITORS BIOGEN, INC. (US) 1996-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML EPHX1 3689/4885RAB9A 1810/4885NPC1 1422/4885
US-20030083267-A1 Cell adhesion inhibitors ICAM1, VCAM1, EPCAM EPHX1 445/4885RAB9A 1779/4885NPC1 2649/4885
US-20030018016-A1 Cell adhesion inhibitors ICAM1, VCAM1, EPCAM EPHX1 445/4885RAB9A 1779/4885NPC1 2649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.